Cisplatin, 5-fluorouracil, and leucovorin in the therapy of adenocarcinomas of the pancreas

D. V. Jones; S. M. Sugarman; A. B. Markowitz; B. Levin; J. L. Abbruzzese; D. B. Evans; C. Charnsangavej; R. Smith; Y. Z. Patt

doi:10.3892/or.2.6.1121

Cisplatin, 5-fluorouracil, and leucovorin in the therapy of adenocarcinomas of the pancreas

D. V. Jones, S. M. Sugarman, A. B. Markowitz, B. Levin, J. L. Abbruzzese, D. B. Evans, C. Charnsangavej, R. Smith, Y. Z. Patt

General Oncology

Research output: Contribution to journal › Article › peer-review

Abstract

Pancreatic cancer is resistant to most chemotherapeutic regimens. Based upon evidence of synergy between 5-fluorouracil (5-FU) and cisplatin (CDDP), and of enhanced 5-FU activity in the presence of leucovorin in other neoplasms, a phase II study of CDDP, 5-FU, and leucovorin was conducted to determine the efficacy of this regimen in patients with unresectable adenocarcinomas of the pancreas. Nineteen patients were enrolled, and all were evaluable for toxicity and response. One complete and two partial responses were observed (15.8%). Adverse effects were reversible and tolerable. This regimen has limited activity against pancreatic cancer, and cannot be recommended as standard therapy in this disease.

Original language	English (US)
Pages (from-to)	1121-1123
Number of pages	3
Journal	Oncology reports
Volume	2
Issue number	6
DOIs	https://doi.org/10.3892/or.2.6.1121
State	Published - 1995

Keywords

5-fluorouracil
Chemotherapy
Cisplatin
Drug synergy
Leucovorin
Pancreatic cancer

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3892/or.2.6.1121

Cite this

@article{a0b1e652ecf548c6bcaa3d711f1aabe6,

title = "Cisplatin, 5-fluorouracil, and leucovorin in the therapy of adenocarcinomas of the pancreas",

abstract = "Pancreatic cancer is resistant to most chemotherapeutic regimens. Based upon evidence of synergy between 5-fluorouracil (5-FU) and cisplatin (CDDP), and of enhanced 5-FU activity in the presence of leucovorin in other neoplasms, a phase II study of CDDP, 5-FU, and leucovorin was conducted to determine the efficacy of this regimen in patients with unresectable adenocarcinomas of the pancreas. Nineteen patients were enrolled, and all were evaluable for toxicity and response. One complete and two partial responses were observed (15.8%). Adverse effects were reversible and tolerable. This regimen has limited activity against pancreatic cancer, and cannot be recommended as standard therapy in this disease.",

keywords = "5-fluorouracil, Chemotherapy, Cisplatin, Drug synergy, Leucovorin, Pancreatic cancer",

author = "Jones, {D. V.} and Sugarman, {S. M.} and Markowitz, {A. B.} and B. Levin and Abbruzzese, {J. L.} and Evans, {D. B.} and C. Charnsangavej and R. Smith and Patt, {Y. Z.}",

year = "1995",

doi = "10.3892/or.2.6.1121",

language = "English (US)",

volume = "2",

pages = "1121--1123",

journal = "Oncology reports",

issn = "1021-335X",

publisher = "Spandidos Publications",

number = "6",

}

TY - JOUR

T1 - Cisplatin, 5-fluorouracil, and leucovorin in the therapy of adenocarcinomas of the pancreas

AU - Jones, D. V.

AU - Sugarman, S. M.

AU - Markowitz, A. B.

AU - Levin, B.

AU - Abbruzzese, J. L.

AU - Evans, D. B.

AU - Charnsangavej, C.

AU - Smith, R.

AU - Patt, Y. Z.

PY - 1995

Y1 - 1995

N2 - Pancreatic cancer is resistant to most chemotherapeutic regimens. Based upon evidence of synergy between 5-fluorouracil (5-FU) and cisplatin (CDDP), and of enhanced 5-FU activity in the presence of leucovorin in other neoplasms, a phase II study of CDDP, 5-FU, and leucovorin was conducted to determine the efficacy of this regimen in patients with unresectable adenocarcinomas of the pancreas. Nineteen patients were enrolled, and all were evaluable for toxicity and response. One complete and two partial responses were observed (15.8%). Adverse effects were reversible and tolerable. This regimen has limited activity against pancreatic cancer, and cannot be recommended as standard therapy in this disease.

AB - Pancreatic cancer is resistant to most chemotherapeutic regimens. Based upon evidence of synergy between 5-fluorouracil (5-FU) and cisplatin (CDDP), and of enhanced 5-FU activity in the presence of leucovorin in other neoplasms, a phase II study of CDDP, 5-FU, and leucovorin was conducted to determine the efficacy of this regimen in patients with unresectable adenocarcinomas of the pancreas. Nineteen patients were enrolled, and all were evaluable for toxicity and response. One complete and two partial responses were observed (15.8%). Adverse effects were reversible and tolerable. This regimen has limited activity against pancreatic cancer, and cannot be recommended as standard therapy in this disease.

KW - 5-fluorouracil

KW - Chemotherapy

KW - Cisplatin

KW - Drug synergy

KW - Leucovorin

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=0028844160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028844160&partnerID=8YFLogxK

U2 - 10.3892/or.2.6.1121

DO - 10.3892/or.2.6.1121

M3 - Article

C2 - 21597866

AN - SCOPUS:0028844160

SN - 1021-335X

VL - 2

SP - 1121

EP - 1123

JO - Oncology reports

JF - Oncology reports

IS - 6

ER -

Cisplatin, 5-fluorouracil, and leucovorin in the therapy of adenocarcinomas of the pancreas

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this